G Pialoux

Summary

Country: France

Publications

  1. ncbi request reprint [HIV vaccines]
    G Pialoux
    Service des maladies infectieuses et tropicales Hôpital Tenon, Paris
    Presse Med 34:1592-6. 2005
  2. ncbi request reprint Chikungunya, an epidemic arbovirosis
    Gilles Pialoux
    Hopital Tenon, Service des Maladies Infectieuses et Tropicales, Paris, France
    Lancet Infect Dis 7:319-27. 2007
  3. ncbi request reprint Effect of HIV infection on the course of syphilis
    Gilles Pialoux
    APHP, Dept of Infectious and Tropical Diseases, Tenon Hospital, Paris, France
    AIDS Rev 10:85-92. 2008
  4. ncbi request reprint [Chikungunya virus infection: review through an epidemic]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, APHP, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Med Mal Infect 36:253-63. 2006
  5. ncbi request reprint [Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, Paris
    Presse Med 34:1589-91. 2005
  6. ncbi request reprint Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study
    Gilles Pialoux
    APHP, Hopital Tenon, 4 rue de la Chine, Paris Cedex 20, France
    Vaccine 26:2657-66. 2008
  7. pmc Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study
    Gilles Pialoux
    APHP, Tenon Hospital, Paris, France
    Clin Vaccine Immunol 15:562-8. 2008
  8. doi request reprint Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
    I Kousignian
    INSERM U, Paris, France
    J Antimicrob Chemother 65:138-44. 2010
  9. ncbi request reprint MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
    C Katlama
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 2:20-6. 2001
  10. doi request reprint A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Paris, France
    J Med Virol 82:1819-28. 2010

Collaborators

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint [HIV vaccines]
    G Pialoux
    Service des maladies infectieuses et tropicales Hôpital Tenon, Paris
    Presse Med 34:1592-6. 2005
    ..Recombinant live vector-based vaccines, lipopeptides, and plasmid DNA have all been shown to induce CTL. The different forms of prime-boost vaccine strategies currently being tested in numerous clinical trials provide reasons for hope...
  2. ncbi request reprint Chikungunya, an epidemic arbovirosis
    Gilles Pialoux
    Hopital Tenon, Service des Maladies Infectieuses et Tropicales, Paris, France
    Lancet Infect Dis 7:319-27. 2007
    ..Plausible explanations include increased tourism, chikungunya virus introduction into a naive population, and viral mutation...
  3. ncbi request reprint Effect of HIV infection on the course of syphilis
    Gilles Pialoux
    APHP, Dept of Infectious and Tropical Diseases, Tenon Hospital, Paris, France
    AIDS Rev 10:85-92. 2008
    ..Early diagnosis of syphilis in HIV-infected patients requires awareness among both patients and clinicians. Early treatment of syphilis is crucial as it reduces the risk of transmission...
  4. ncbi request reprint [Chikungunya virus infection: review through an epidemic]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, APHP, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Med Mal Infect 36:253-63. 2006
    ..This is also the first time that a Chikungunya epidemic is described in this part of the world...
  5. ncbi request reprint [Efficacy of peginterferon plus ribavirin for HIV-HCV co-infection. Results of the APRICOT study]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, Paris
    Presse Med 34:1589-91. 2005
    ..It should also be the preferred treatment for patients with HIV-HCV coinfection...
  6. ncbi request reprint Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study
    Gilles Pialoux
    APHP, Hopital Tenon, 4 rue de la Chine, Paris Cedex 20, France
    Vaccine 26:2657-66. 2008
    ..No anti-gp160 activity was found between week 4 and week 48 in serum, saliva, or cervicovaginal and nasal secretions. These results show that a mucosal HIV vaccine can be well tolerated when administered by the nasal or vaginal route...
  7. pmc Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study
    Gilles Pialoux
    APHP, Tenon Hospital, Paris, France
    Clin Vaccine Immunol 15:562-8. 2008
    ..Despite the lack of a control arm, these findings warrant a randomized study of therapeutic vaccination with HIV lipopeptides followed by long-term HAART interruption in AIDS-free chronically infected patients...
  8. doi request reprint Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
    I Kousignian
    INSERM U, Paris, France
    J Antimicrob Chemother 65:138-44. 2010
    ....
  9. ncbi request reprint MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
    C Katlama
    Service des Maladies Infectieuses, Hopital Pitie Salpetriere, Paris, France
    HIV Med 2:20-6. 2001
    ..Since eradication of HIV is unlikely, long-term management of the disease necessitates careful evaluation of the combinations of currently available drugs to determine the most potent and useful rational sequencing of regimens...
  10. doi request reprint A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Paris, France
    J Med Virol 82:1819-28. 2010
    ..A high PBMC HIV DNA level at TI was a strong predictor for more rapid treatment resumption...
  11. pmc Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy
    Laurence Weiss
    Faculte de Medecine, Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Europeen Georges Pompidou, Paris, France
    PLoS ONE 5:e11659. 2010
    ..However, the insufficient increase in the proportion and/or the decrease in the absolute number of Tregs result in a failure to control immune activation following TI...
  12. ncbi request reprint Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
    David Saadoun
    Department of Internal Medicine, Service de Medecine Interne, AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Ann Rheum Dis 73:831-7. 2014
    ..About 30-40% of patients are non-responders or relapsers to such combination...
  13. doi request reprint Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  14. ncbi request reprint Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy
    C Besson
    Hopital Necker, SC4 INSERM, CHU Pitie Salpetriere, Hopital Rothschild, Paris, France
    Blood 98:2339-44. 2001
    ..004). Therefore, the profile of ARL has changed since the era of HAART, with a lower incidence of systemic and brain ARL. The prognosis of systemic ARL has improved...
  15. pmc Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    J J Laurichesse
    Laboratoire de Recherche en Pathologie Infectieuse, Universite Paris 7, Paris, France
    HIV Med 11:239-44. 2010
    ..The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients...
  16. ncbi request reprint Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus
    David Saadoun
    Service de Medecine Interne, hôpital La Pitié Salpêtrière, Paris, France
    AIDS 20:871-7. 2006
    ..To describe mixed cryoglobulinaemia (MC) vasculitis in patients coinfected with hepatitis C virus (HCV) and HIV...
  17. doi request reprint Liver stiffness values in HIV-infected patients with isolated anti-hepatitis B core antibodies
    C Chakvetadze
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Med Mal Infect 43:222-5. 2013
    ..Hepatitis B reactivation has been observed in HIV-infected patients with isolated anti-HBc. However, the impact of isolated anti-HBc on liver fibrosis is not known in this population...
  18. ncbi request reprint [Bobo Dioulasso Teaching Hospital day-care hospital: a reference structure for the management of HIV infected patients in Burkina Faso]
    C Fontaine
    Service des Maladies Infectieuses et Tropicales, centre hospitalo universitaire de Tenon, AP HP, 4, rue de la Chine, 75020 Paris, France
    Med Mal Infect 40:393-7. 2010
    ..The goal of the study was to assess the activity of a multidisciplinary structure for HIV infected patients, two years after the opening of the day hospital...
  19. doi request reprint Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study
    H Ait-Mohand
    Service de Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Pitie Salpetriere, Paris, France
    HIV Med 9:738-46. 2008
    ..Stavudine (d4T) is a potent but potentially toxic nucleoside reverse transcriptase inhibitor that is still widely used in developing countries. This study's aim was to determine the efficacy and safety profile of lower-dose d4T...
  20. doi request reprint Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  21. ncbi request reprint Metabolic disorders and chronic viral disease: the case of HIV and HCV
    L Slama
    Service des Maladies Infectieuses, Hopital Tenon, AP HP, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Diabetes Metab 35:1-11. 2009
    ..Recent data indicate that HCV clearance improves insulin resistance and hepatic function in HCV-infected patients treated with interferon with or without ribavirin...
  22. pmc CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART
    D Scott-Algara
    Unité d Immuno Hématologie et d Immuno Pathologie, Institut Pasteur, Paris, France
    Clin Exp Immunol 126:295-303. 2001
    ..We conclude that permanent control of HIV replication could be necessary for faster immune reconstitution...
  23. doi request reprint How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
    ....
  24. doi request reprint Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  25. pmc X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  26. doi request reprint Tenosynovitis as a possible feature of immune reconstitution syndrome during highly active antiretroviral treatment (HAART)
    Claire Rivoisy
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, AP HP, Paris, France
    Joint Bone Spine 76:550-2. 2009
    ..This original case increase the broad spectrum of inflammatory rheumatologic disorders associated with HIV infection...
  27. doi request reprint Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
    AIDS 22:1203-11. 2008
    ..To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer...
  28. ncbi request reprint [Adherence to antiretroviral therapy during HIV infection, a multidisciplinary approach]
    L Slama
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 4, rue de la Chine, 75020 Paris, France
    Med Mal Infect 36:16-26. 2006
    ..And the methods implemented by numerous healthcare teams plead in favour of a dynamic approach to adherence, with the active participation of all...
  29. ncbi request reprint Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus
    Aurelie Schnuriger
    INSERM, UMRS 945, Paris, France
    AIDS 23:2079-89. 2009
    ..To explore the parameters of specific immunity to hepatitis C virus (HCV) associated with virus clearance during acute HCV infection in HIV coinfection...
  30. doi request reprint The risk of going abroad in sickle cell disease: a study of 148 adults
    K Stankovic Stojanovic
    Internal Medicine Department, Referral Centre for Adult Sickle Cell Disease, Assistance Public Hospital of Paris, Tenon Hospital, Paris, France
    Trans R Soc Trop Med Hyg 105:310-4. 2011
    ..Our study showed that going abroad is associated with a large number of acute complications in adults with SCD. Complications were mostly VOC, and severity was unpredictable. Prevention should be improved...
  31. doi request reprint Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene
    C Amiel
    UPMC Paris 6, Paris, France
    HIV Med 12:138-44. 2011
    ..The aim of the study was to assess the long-term viro-immunological follow-up of HIV-infected patients harbouring virus with protease insertions...
  32. ncbi request reprint Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial
    Fabrice Carrat
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, Paris, France
    JAMA 292:2839-48. 2004
    ..Most data on the virologic efficacy and safety of the combination of peginterferon alfa-2b and ribavirin in coinfected patients come from uncontrolled studies...
  33. doi request reprint Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
    L Michel
    INSERM U669, Paris, France
    J Viral Hepat 17:650-60. 2010
    ....
  34. doi request reprint Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
    S Grabar
    Department of Public Health, Cochin Hospital, Paris, France
    HIV Med 9:246-56. 2008
    ....
  35. ncbi request reprint Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers
    G Pialoux
    Hopital Rothschild, Paris, France
    AIDS 15:1239-49. 2001
    ..Test the efficacy of a mixture of six NEF (N1, N2, N3), GAG (G1, G2) and ENV (E) lipopeptides in the induction of B- and T-cell anti-HIV responses...
  36. ncbi request reprint Reversible ALS-like disorder in HIV infection
    A Moulignier
    Fondation Adolphe de Rothschild, Service de Neurologie, Paris, France
    Neurology 57:995-1001. 2001
    ..To describe the clinical features, treatment, and outcome of six cases of HIV-1-associated ALS-like disorder...
  37. doi request reprint Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007
    Pierre Charles
    Universite Paris Descartes, Hopital Necker Enfants Malades, Paris, France
    Medicine (Baltimore) 90:223-30. 2011
    ..The 1-year survival rate was 72%.The prognosis of M. genavense infection in HIV-infected patients has dramatically improved with HAART. Clinical presentations in HIV and non-HIV immunocompromised patients were similar...
  38. ncbi request reprint Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex
    G Pialoux
    , Paris, France
    Lancet 338:140-3. 1991
    ....
  39. doi request reprint [Chagas disease]
    M Develoux
    Service de Parasitologie, Hopital Saint Antoine, AP HP, 184, rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Rev Med Interne 30:686-95. 2009
    ..There is an urgent need for new treatments and better serological tests. Policies must be developed to avoid the risk of transmission trough blood transfusion and transplantation in developed countries...
  40. ncbi request reprint [Emergence of Chagas' disease in Europe: description of the first cases observed in Latin American immigrants in mainland France]
    M Develoux
    Service des Maladies Infectieuses et Tropicales, Hôpital Tenon APHP
    Med Trop (Mars) 70:38-42. 2010
    ..Based on these findings, the main priorities for management imported Chagas' disease in France are improvement of serological diagnosis and prevention of vertical transmission...
  41. doi request reprint Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance
    Jean Michel Molina
    Service des Maladies Infectieuses et Tropicales, Hôpital Saint Louis and University of Paris Diderot, Paris 7, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Antimicrob Chemother 64:398-410. 2009
    ....
  42. pmc Chagas disease, France
    Francois Xavier Lescure
    Hopital Tenon AP HP, Paris, France
    Emerg Infect Dis 14:644-6. 2008
    ..CD is sometimes seen in the United States and Canada among migrants from Latin America, whereas it is rare in Europe. We report 9 cases of imported CD in France from 2004 to 2006...
  43. ncbi request reprint Factors predictive of virological failure on atazanavir in 310 HIV-infected patients
    Francois Xavier Lescure
    Service de Maladies Infectieuses et Tropicales, APHP Hôpital Tenon and Université Pierre et Marie Curie, France Paris, France
    AIDS 24:1593-5. 2010
    ....
  44. ncbi request reprint [Management of HCV-HIV patients]
    Stanislas Pol
    Unité d Hépatologie, Hopital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris
    Gastroenterol Clin Biol 31:4S7-12. 2007
    ..The harmful impact of HIV underlines the need for improving:..
  45. ncbi request reprint Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006
    Patrice Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    J Hepatol 48:35-42. 2008
    ..To analyze the barriers to HCV treatment in HIV-HCV co-infected patients and their evolution between 2004 and 2006...
  46. pmc Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    PLoS ONE 2:e725. 2007
    ..The objective was to compare the safety and cellular immunogenicity of intradermal versus intramuscular immunization with an HIV-lipopeptide candidate vaccine (LIPO-4) in healthy volunteers...
  47. doi request reprint Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    Dominique Salmon-Ceron
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Cochin, France
    AIDS 24:2211-23. 2010
    ..Whether HIV-LIPO-5 immunogenicity varies with the dose is unknown...
  48. ncbi request reprint Chagas disease: changes in knowledge and management
    Francois Xavier Lescure
    APHP Hôpital Tenon, Universite Pierre et Marie Curie, Paris, France
    Lancet Infect Dis 10:556-70. 2010
    ..Mobilisation of financial resources to fund research on diagnosis and randomised controlled trials of treatment are international health priorities...
  49. ncbi request reprint Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer
    Armelle Lavole
    Service de Pneumologie et Reanimation, Hopital Tenon, APHP and Faculté de Médecine Pierre et Marie Curie, Universite Paris VI, Paris, France
    Lung Cancer 65:345-50. 2009
    ..To evaluate the impact of highly active antiretroviral therapy (HAART) on survival in HIV infected patients with non-small-cell lung cancer (NSCLC)...
  50. ncbi request reprint Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count
    P Bonnard
    Infectious Diseases Department, Tenon Hospital, AP HP, GHU Paris Est, Université Pierre et Marie Curie UPMC, Paris, France
    J Viral Hepat 14:806-11. 2007
    ..The second biopsy showed that 15 patients (45%) qualified for anti-HCV therapy. Development of noninvasive methods of fibrosis evaluation should permit more frequent monitoring...
  51. doi request reprint [Chagas disease: clinical aspects and treatment in non-endemic countries]
    Guillaume Le Loup
    Clinique du voyage et des maladies d importation, Service des Maladies Infectieuses et Tropicales, Hopital Tenon, AP HP, F 75020 Paris, France
    Presse Med 38:1654-66. 2009
    ..Treatment must be considered on an individual basis in patients older than 50 years. The frequency and seriousness of potential adverse events due to treatment require careful monitoring of the patient throughout treatment...
  52. doi request reprint Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy
    Ana Canestri
    Hopital Pitie Salpetriere, Paris, France
    Clin Infect Dis 50:773-8. 2010
    ..We report data on 11 patients with neurological symptoms and human immunodeficiency virus (HIV) cerebrospinal fluid (CSF) viremia contrasting with suppressed plasma HIV RNA during receipt of combined antiretroviral therapy...
  53. ncbi request reprint Use of well-defined HIV-derived epitopes to evaluate CD4(+) and CD8(+) T cell responses in patients with chronic HIV-1 infection treated with HAART
    Nathalie Daniel
    Department of Immunology, Cochin Institute, INSERM U567, CNRS UMR 8104, Rene Descartes University, Department of Internal Medicine, Cochin Hospital, Paris, France
    AIDS Res Hum Retroviruses 20:827-35. 2004
    ..In conclusion, the experimental approach used in this study shows that CD4(+) T cell responses may persist during HAART but are not associated with strong CD8(+) T cell responses..
  54. pmc Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso
    Philippe Bonnard
    Maladies Infectieuses, Hopital Tenon, UPMC Univ Paris 06, UPMC Paris Liver Center, Paris, France
    Am J Trop Med Hyg 82:454-8. 2010
    ..This study shows that the results of alternative methods concord with those of histology in HBV-infected patients in Burkina Faso. These alternative techniques could help physicians to identify patients requiring treatment...
  55. doi request reprint Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
    ..Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection...
  56. ncbi request reprint [Experience of targeted screening of Chagas disease in Ile-de-France]
    F X Lescure
    Service de Maladies Infectieuses et Tropicales, AP HP, Hopital Tenon, 4, rue de la Chine, F 75020 Paris, France
    Bull Soc Pathol Exot 102:295-9. 2009
    ..These results also demonstrate continuing difficulties in the interpretation of serological results and the usefulness of PCR, which might increase sensitivity substantially...
  57. doi request reprint Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
    M A Valantin
    Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 65:556-61. 2010
    ..To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters...
  58. ncbi request reprint Infection due to Klebsiella rhinoscleromatis in two patients infected with human immunodeficiency virus
    C Paul
    Hospital of the Pasteur Institute, Department of Infectious and Tropical Diseases, Paris, France
    Clin Infect Dis 16:441-2. 1993
    ..The importance of Klebsiella rhinoscleromatis infection in AIDS-related oropharyngeal pathology and the possible treatment of such infection in HIV-positive patients are not yet clearly established...
  59. doi request reprint Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
    Christine Katlama
    Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
    AIDS 23:2289-300. 2009
    ....
  60. ncbi request reprint Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV
    Karine Lacombe
    INSERM U707, Paris, France
    AIDS 20:419-27. 2006
    ..Little is know about the determinants of liver fibrosis progression and genomic variability in hepatitis B virus (HBV) in HIV/HBV-coinfected patients...
  61. ncbi request reprint Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment
    Firouzé Bani-Sadr
    INSERM U707, Faculte de Medecine Hopital Saint Antoine, Paris, France
    Clin Infect Dis 41:1806-9. 2005
    ..02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly...
  62. ncbi request reprint The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002
    Cecile Vigneau
    Department of Nephrology A, Tenon Hospital, Paris, France
    Kidney Int 67:1509-14. 2005
    ..In 1997, 0.38% of dialysis patients in France were infected by human immunodeficiency virus (HIV). No prevalence data were available in France since the widespread introduction of highly active antiretroviral therapy...
  63. pmc High variability of plasma drug concentrations in dual protease inhibitor regimens
    Jean Baptiste Guiard-Schmid
    Department of Clinical Infectious and Tropical Diseases, Tenon Hospital, Paris, France
    Antimicrob Agents Chemother 47:986-90. 2003
    ....
  64. ncbi request reprint Increased CD1-positive cells in peripheral blood of AIDS and ARC patients
    S Chollet Martin
    INSERM U 294, C H U Xavier Bichat, Paris, France
    Immunol Lett 17:53-7. 1988
    ..Further investigations are warranted to assess the biological and clinical relevance of these findings...
  65. ncbi request reprint [Co-infection with HIV and viral hepatitis C]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 4, rue de la Chine, 75020 Paris, France
    Med Mal Infect 36:S218-23. 2006
  66. ncbi request reprint Interleukin-2 receptor beta and gamma chain dysregulation during the inhibition of CD4 T cell activation by human immunodeficiency virus-1 gp120
    L Bani
    Departement d Immunologie, Institut Pasteur, Paris, France
    Eur J Immunol 27:2188-94. 1997
    ..This is the first study of IL-2R beta and IL-2R gamma dysregulation in the context of HIV infection and shows that CD4 is also involved in IL-2R expression...
  67. doi request reprint HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  68. ncbi request reprint A case of ciguatera fish poisoning in a French traveler
    M Develoux
    Service des Maladies Infectieuses et Tropicales, Hôpital Tenon APHP, Paris, France
    Euro Surveill 13:pii: 19027. 2008
    ..Ciguatera is a toxic poisoning due to ingestion of fish and is rarely reported in France. Little is known about this imported tropical disease. We present a case observed in Paris in a traveller returning from the Dominican Republic...
  69. ncbi request reprint Genital tract actinomycosis caused by Actimyces israëlii
    R Quercia
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 4, rue de la Chine, 75970 Paris Cedex 20, France
    Med Mal Infect 36:393-5. 2006
    ..All abdominal organs may be affected. Even with a disseminated infection, the combination of appropriate antibiotic therapy (penicillin G) and surgery ensures a full recovery in most cases...
  70. ncbi request reprint [Hepatic steatosis: an emerging cause of cirrhosis in HIV patients]
    P Loulergue
    Service des Maladies Infectieuses et Tropicales, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Pathol Biol (Paris) 54:587-90. 2006
    ..The implication of HAART remains unclear. In the era of HAART, liver steatosis can rapidly evoluate to cirrhosis without any risk factor except ART...
  71. ncbi request reprint Nephropathy associated with the diffuse infiltrative lymphocytosis syndrome
    L Zafrani
    APHP, Hopital Tenon, Urgences Néphrologiques and Transplantation Rénale, et Université Pierre et Marie Curie UPMC, Paris, France
    Kidney Int 72:219-24. 2007
  72. ncbi request reprint Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study
    L Beaugerie
    Hopital Rothschild, Paris, France
    Eur J Gastroenterol Hepatol 8:485-9. 1996
    ....
  73. ncbi request reprint [Interpretation of transaminase level increase in patients with HIV-HCV or HIV-HBV co-infection]
    G Pialoux
    Service des Maladies Infectieuses et Tropicales, GHU Paris Est, Hopital Tenon, 4, rue de Chine, 75020 Paris, France
    Med Mal Infect 34:12-3. 2004
  74. ncbi request reprint [Liver toxicity of antiretroviral treatments]
    Gilles Pialoux
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, Paris
    Gastroenterol Clin Biol 27:155-8. 2003
  75. doi request reprint Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers
    Benjamin Silbermann
    AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, CIC de vaccinologie Cochin Pasteur, Pôle de médecine, Paris, France
    AIDS Res Hum Retroviruses 24:1445-8. 2008
    ..Because rgp160 induces long-term persistence (>8 years) of vaccine-induced HIV seropositivity, volunteers should be offered long-term follow-up to monitor their serological evolution...
  76. doi request reprint Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen
    Catherine Chakvetadze
    Service des Maladies Infectieuses et Tropicales, Hopital Tenon, 75 970 Paris, France
    Clin Infect Dis 50:1184-6. 2010
    ..No baseline factors were found to be predictive of an anamnestic response, which occurred in 32.5% of the patients. The overall response rate among patients without an anamnestic response was 74.0% after 3-6 vaccine doses...
  77. ncbi request reprint Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients
    Stephanie Dominguez
    Department of Infectious and Tropical Diseases INSERM U 720, CHU Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 20:1157-61. 2006
    ..Treatment of acute hepatitis C (HCV) in HIV-infected patients has been poorly addressed...
  78. ncbi request reprint Outbreak of syphilis among HIV-infected patients: descriptive data from a Parisian hospital
    Bruno Abraham
    Sex Transm Dis 32:718-9. 2005
  79. ncbi request reprint Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials
    Philippe Flandre
    INSERM Unité 720, 56 Boulevard Vincent Auriol, 75625 Paris Cedex 13, France
    HIV Clin Trials 7:116-24. 2006
    ..We applied the different models to data from a clinical trial in HIV-1-infected patients...
  80. ncbi request reprint Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate
    Camille Fontaine
    AIDS 19:1927-8. 2005
  81. ncbi request reprint Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy
    Firouzé Bani-Sadr
    Groupe Hospitalier Universitaire Est, Universite Paris 6, INSERM U444, France
    J Acquir Immune Defic Syndr 40:47-52. 2005
    ..To evaluate the incidence, clinical features, and risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving anti-HCV therapy...
  82. ncbi request reprint Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
    Eric Rosenthal
    Service d Hematologie Clinique, Hopital Archet, Nice, France
    AIDS 17:1803-9. 2003
    ....
  83. ncbi request reprint Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients
    Nathalie Daniel
    AIDS 17:2126-9. 2003
  84. ncbi request reprint Final analysis of the Trilège induction-maintenance trial: results at 18 months
    Philippe Flandre
    INSERM SC10, Hopital Paul Brousse, 16 avenue Paull Vaillant Couturier, 94807 Villejuif Cedex, France
    AIDS 16:561-8. 2002
    ..First results of Trilège demonstrated that the strategy of less intensive antiviral therapy is less effective than continuation of triple-drug therapy...
  85. pmc Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized
    Hanne Gahéry-Ségard
    Département d Immunologie Membre de l IFR 116 INSERM U567, Institut Cochin, 75014 Paris, France
    J Virol 77:11220-31. 2003
    ..05 compared to three injections), which indicates an increase in the breadth of HIV CD8(+)-T-cell epitope recognition after the boost...
  86. doi request reprint Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfected patients
    Fabrice Carrat
    UPMC Paris6, UMR S707, INSERM, UMR S707, Saint Antoine Hospital, Assistance Publique Hopitaux de Paris, France
    AIDS 22:1513-5. 2008
    ..83; 95% confidence interval 1.05-3.20). Serum alpha-fetoprotein measurement should be integrated in the pretreatment assessment of prognostic factors of a virologic response...
  87. ncbi request reprint Hepatic steatosis as an emerging cause of cirrhosis in HIV-infected patients
    Pierre Loulergue
    J Acquir Immune Defic Syndr 45:365. 2007
  88. ncbi request reprint Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies
    Catherine Chakvetadze
    AIDS 21:393-4. 2007
  89. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  90. ncbi request reprint Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study
    Christian Mouala
    INSERM, U720, Paris, F 75013 France
    J Acquir Immune Defic Syndr 49:55-60. 2008
    ..To describe episodes of imported malaria in human immunodeficiency virus type 1-infected patients and to study the risk factors for severe Plasmodium falciparum malaria...
  91. ncbi request reprint New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine
    Hanne Gahery
    Institut Cochin, Departement d Immunologie, INSERM U567, CNRS UMR8104, Universite Rene Descartes, 75014 Paris, France
    AIDS Res Hum Retroviruses 22:684-94. 2006
    ..Lipopeptides induce new anti-HIV T cell responses in vaccinated infected patients and could be used as a new immunotherapy strategy. The majority of these responders induced specific new CD4(+) and CD8(+) T cell responses...
  92. ncbi request reprint Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen
    Romina Quercia
    J Acquir Immune Defic Syndr 42:389-90. 2006
  93. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  94. ncbi request reprint Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors
    Jean Marie Poirier
    AIDS 20:1087-9. 2006
  95. ncbi request reprint Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
    José Valdez Madruga
    Centro de Referência e Treinamento DST AIDS, Sao Paulo, Brazil
    Lancet 370:29-38. 2007
    ..The aim of this trial was to assess the efficacy, safety, and tolerability of TMC125 (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI)...
  96. ncbi request reprint Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults
    Christine Durier
    INSERM SC10, 16 Avenue Paul Caillant Couturier, 94800 Villejuif, France
    AIDS 20:1039-49. 2006
    ..The aim of this study was to review clinical safety of HIV lipopeptides...
  97. ncbi request reprint Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)
    Lionel Piroth
    Service de Maladies Infectieuses et Tropicales, CHU Dijon, 10 boulevard du Maréchal de Lattre de Tassigny, 21079 Dijon Cedex, France
    AIDS 21:1323-31. 2007
    ..To describe the characteristics of hepatitis B (HBV) infection in HIV-infected patients and the impact of anti-HBV treatments...
  98. ncbi request reprint Mycobacterium sherrisii: a new opportunistic agent in HIV infection?
    Pierre Loulergue
    AIDS 21:893-4. 2007
  99. ncbi request reprint Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients
    Marie Emilienne Diop
    AP HP, Hopital Tenon, Service de biochimie et d hormonologie, and Université Pierre et Marie Curie Paris 6, Faculte de Medecine, F 75020 France
    AIDS Res Hum Retroviruses 22:1242-7. 2006
    ..Self-monitoring of blood glucose and search for latent hemolysis should be promoted in diabetic HIV-infected patients...
  100. ncbi request reprint Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/microl: a role for IL-2 therapy?
    Camille Fontaine
    AIDS 20:1680-1. 2006
  101. ncbi request reprint Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir
    Jean Baptiste Guiard-Schmid
    AIDS 19:1937-8. 2005